PTEN (Phosphatase and tensin homolog deleted on chromosome 10) expression in stromal fibroblasts suppresses epithelial mammary tumours, but the underlying molecular mechanisms remain unknown. Using proteomic and expression profiling, we show that Pten loss from mammary stromal fibroblasts activates an oncogenic secretome that orchestrates the transcriptional reprogramming of other cell types in the microenvironment. Downregulation of miR-320 and upregulation of one of its direct targets, ETS2 (v-ets erythroblastosis virus E26 oncogene homolog 2) are critical events in Pten-deleted stromal fibroblasts responsible for inducing this oncogenic secretome, which in turn promotes tumour angiogenesis and tumour-cell invasion. Expression of the Pten-miR-320-Ets2 -regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
transcription factor ETS2 (ref. 6) . Importantly, this work demonstrated that decreased PTEN protein levels were frequently observed in the stroma of human invasive-breast-cancer patients and were inversely correlated with the stromal expression of activated phosphorylated v-akt murine thymoma viral oncoprotein homolog 1 (AKT, also known as AKT1) and ETS2. In this report we show that Pten loss reprogrammes messenger RNA and microRNA (miR) expression profiles in normal mammary stromal fibroblasts to elicit a tumour-associated fibroblast phenotype and the reprogramming of gene expression in the entire mammary-gland microenvironment. While there is extensive evidence supporting a role for miRs in tumour cells 7, 8 , little is known about their regulation in stromal fibroblasts and whether they participate in the communication between the different cellular compartments of the tumour microenvironment. We show that miR-320 is a critical target of PTEN in stromal fibroblasts that directly controls ETS2 expression and instructs the tumour microenvironment to suppress many of the aggressive phenotypes associated with advanced stages of breast cancer, including tumour-cell invasiveness and increased angiogenic networks.
RESULTS

Pten loss in stromal fibroblasts reprogrammes gene expression in the mammary-gland microenvironment
To explore the mechanism of how PTEN-mediated signalling in stromal fibroblasts elicits tumour suppression, we compared expression of miRs in mouse mammary fibroblasts (MMFs) containing or lacking Pten. The Fsp-cre transgene and a conditional allele of Pten previously established in our laboratory were used to carry out fibroblast-specific deletion of Pten in mammary glands of mice (Fsp-cre;Pten loxP/loxP ; ref. 9) . Of 400 miRs profiled, ten miRs conserved between mouse and human genomes were significantly downregulated at least twofold in Pten-deleted MMFs (Supplementary Table S1 ). Quantitative real-time PCR (qrtPCR) confirmed reduced expression of nine of the ten relevant miRs in Pten-null fibroblasts ( Fig. 1a and Supplementary Table S1 ).
Together, these observations indicate that Pten loss influences mRNA (ref. 6 ) and miR profiles in mammary stromal fibroblasts.
We then entertained the possibility that the specific ablation of Pten in MMFs could lead to the reprogramming of gene expression in other cell compartments of the mammary gland. Analysis of mRNA expression profiles derived from epithelial and endothelial cells purified from Pten loxP/loxP and Fsp-cre;Pten loxP/loxP mammary glands revealed distinct sets of genes that were differentially expressed dependent on the status of Pten in mammary fibroblasts ( Fig. 1b and Supplementary Fig. S1a ).
miR-320 in fibroblasts suppresses tumour-cell growth in vivo
Because miRs impact wide networks of gene expression 10 , we focused on miRs in mammary stromal fibroblasts that could potentially function to communicate Pten signalling to the other cells in the microenvironment. We selected miR-320 for further analysis because it was the only miR of the nine conserved murine miRs to be reported to be downregulated in human breast cancer [11] [12] [13] [14] [15] and because relatively little is known about its function. In four pairs of independently isolated MMF populations, miR-320 expression was significantly reduced when Pten was ablated and was inversely correlated with expression of the critical PTEN target ETS2 ( Supplementary Fig. S1b ). To test whether decreased miR-320 expression had any functional consequence on the behaviour of mammary epithelial tumour cells, we ectopically expressed miR-320 in Pten-null MMFs ( Supplementary Fig. S2d ) and evaluated their capacity to support epithelial tumour-cell growth in xenograft assays. A mouse mammary epithelial tumour-cell line expressing a variant of the polyoma virus middle T-antigen gene (DB7; ref. 16 ) was tagged with dsRed and co-injected with enhanced green fluorescent protein (GFP)-tagged MMFs into immunocompromised mice. When compared with the co-injection of Pten +/+ MMFs, the co-injection of Pten −/− MMFs increased tumour growth fourfold, whereas restoration of miR-320 expression in the Pten −/− MMFs significantly reduced tumour growth (Fig. 1c) . Differences in tumour size were due almost exclusively to an increase in the epithelial tumour-cell compartment, as determined by the ratio of dsRed tumour cells to enhanced GFP MMFs visualized by confocal microscopy ( Supplementary Fig. S2a ). Importantly, tumours derived from DB7 cells co-injected with Pten −/− MMFs expressing miR-320 were less invasive and had diminished vasculature when compared with tumours from DB7 cells co-injected with Pten −/− MMFs ( Supplementary Fig. S2b,c) . To capture the direct effects of fibroblasts on the tumorigenicity of epithelial cells without the potential confounding effects of infiltrating host stromal cells, we transiently expressed miR-320 or anti-miR-320 in MMFs and analysed the consequences on DB7 tumour cells at an earlier time in tumour development. These experiments had two complementary arms. First, co-injection of DB7 cells with Pten −/− MMFs was compared with the co-injection of DB7 with Pten −/− MMFs re-expressing miR-320. In this set of experiments, tumour-cell proliferation, measured by 5-bromodeoxyuridine (BrdU) incorporation, decreased by approximately 30% with miR-320 reexpression in Pten −/− MMFs (Fig. 1d, top panels) . The formation of new blood vessels in these tumours, as measured by CD31 (platelet/endothelial cell adhesion molecule, also known as PECAM1) immunostaining, was also significantly decreased by the re-expression of miR-320 in Pten −/− MMFs (Fig. 1e , top panels). In the complementary second set of experiments, DB7 cells were coinjected with Pten +/+ MMFs or with Pten +/+ MMFs knocked down for endogenous miR-320 (through anti-miR, see Supplementary  Fig. S2e ). In these experiments, tumour-cell proliferation increased by approximately 25% with knockdown of miR-320 in Pten +/+ MMFs (Fig. 1d, bottom panels) . Similarly, the formation of new blood vessels was markedly increased by anti-miR-320 knockdown (Fig. 1e, bottom panels) . Taken together, these results uncover a cell-non-autonomous tumour-suppressor role for miR-320 in stromal fibroblasts.
miR-320 and PTEN expression are correlated in human breast cancer stroma but not in the tumour
We then examined stromal and epithelial expression of miR-320 in a panel of human invasive breast carcinoma and matched normal samples from 126 patients by in situ hybridization 17 . The human genome contains eight annotated MIR320 genes that encode five mature miR variants; the mouse has an orthologue for only one of these, miR-320a. We used the Mir320a sequence to design the locked oligonucleotide probe used for this analysis; however, all five variant miRs would probably be detected with the hybridization conditions used. Robust miR-320 expression was detected in the epithelial and stromal cell compartments of normal breast tissue but was consistently reduced in both cell compartments of invasive carcinoma samples (multispectral blue-channel images and quantification in Fig. 2a , light microscope images in Supplementary Fig. S3a ). Some nuclear staining for miR-320 was also evident. This nuclear staining could be explained either by probe hybridization to nuclear pre-miR forms or by nuclear re-localization of the mature miR (refs 18-22) .
Multispectral imaging of samples stained for both PTEN and miR-320 demonstrated that their expression could be co-localized in the tumour stroma ( Fig. 2b and Supplementary Fig. S3b ). When the staining of PTEN and miR-320 was scored, a significant positive correlation between PTEN and miR-320 expression in the tumour stroma was revealed (Spearman rho = 0.24, P = 0.004, Supplementary  Table S2 ). In contrast, there was no significant correlation between PTEN and miR-320 in the epithelial tumour-cell compartment of the same tissue microarray (TMA) samples (Spearman rho = 0.093, P = 0.268). Interestingly, a significant inverse correlation was found between PTEN expression in the tumour and tumour stroma, whereas a strong positive correlation was found between miR-320 expression in the tumour and tumour stroma (Supplementary Table S2 ), suggesting that downregulation of miR-320 in the stroma and tumour compartments may be mediated through distinct mechanisms. Given the established relationship between PTEN function and ETS2 (ref. 6), we used these tissue arrays to examine the phosphorylation status of Thr 72 in ETS2 (P-ETS2 T72 ), which corresponds to its active state as a transcriptional activator. This analysis revealed that P-ETS2 T72 levels inversely correlated with miR-320 levels in breast carcinoma samples (Spearman correlation coefficient −0.166, P = 0.04, Supplementary Table S2 ). The correlative human data raised the possibility of a functional connection between PTEN and miR-320 in blocking the function of ETS2 in stromal fibroblasts in a way that might bias the mammary gland microenvironment towards tumour suppression. miR-320 in stromal fibroblasts suppresses tumour-cell and endothelial-cell proliferation and invasion in vitro Increased proliferation and migration of epithelial cells with concurrent epithelial-mesenchymal transition are hallmarks of malignant tumour growth 23, 24 . Stromal fibroblasts are known to produce factors that signal to other cell types in the tumour microenvironment 25 . To determine whether miR-320 in stromal fibroblasts influences the invasiveness of epithelial tumour cells, we developed a three-dimensional sphere invasion assay to monitor and quantify the migration of a non-invasive breast cancer tumour-cell line (DB7). As monitored by microscopy, DB7 epithelial tumour cells embedded in a type I collagen matrix did not migrate to any appreciable extent when incubated with either fresh media or conditioned media derived from wild-type MMFs (Fig. 3a , left and middle panels). In contrast, migration was markedly increased when DB7 cells were incubated with conditioned medium from Pten-null MMFs (Fig. 3a, right panel) . Interestingly, conditioned media from Pten-null MMFs elicited morphological changes in DB7 cells that resembled epithelial-mesenchymal transition (Fig. 3a , magnified insets). Using this invasion assay, we could show that re-expression of miR-320 in Pten-null MMFs attenuated the migration capacity of DB7 cells and also restored their typical cuboidal epithelial morphology (Fig. 3b) . BrdU-incorporation assays demonstrated that conditioned media from Pten-null MMFs overexpressing miR-320 eventually led to a modest but consistent decrease in the proliferation of DB7 cells (Fig. 3c) . Because co-injection of DB7 cells with MMFs lacking Pten or miR-320 resulted in highly vascular tumours, we examined whether miR-320 in MMFs might directly influence the behaviour of endothelial cells using three-dimensional tube formation assays. Conditioned media from Pten-null MMFs stimulated the invasion of endothelial cells into matrigel and enhanced their arrangement into branched, tube-like structures, whereas conditioned media from miR-320-expressing Ptennull MMFs mitigated these effects (Fig. 3d) . Moreover, conditioned media from Pten-null MMFs overexpressing miR-320 led to a decrease in the proliferation of endothelial cells when compared with control ( Fig. 3e) . Thus, we conclude that miR-320 in stromal fibroblasts profoundly influences the behaviour of other cell types in the tumour microenvironment through the action of secreted factors.
Stromal miR-320 regulates a tumour-specific secretome
We used a proteomic approach to identify the miR-320-regulated factors secreted by fibroblasts that modulate tumour-and endothelialcell function. Mass spectrometry analysis of unfractionated, conditioned media from Pten-null MMFs, expressing either miR-320 or a negative control miR, identified 51 secreted proteins that were differentially represented, with 32 unique proteins present in the conditioned media from control Pten-null MMFs and 19 proteins unique to the conditioned media from miR-320-expressing Pten-null MMFs ( Supplementary Fig. S4a ,b and Table S3 ).
Western blot analysis on a subset of these proteins confirmed their differential secretion and also identified quantitative changes in the level of three more secreted proteins that were not reproducibly detected by mass spectrometry, giving rise to a miR-320-responsive secretome profile of 54 factors ( Fig. 4a and Supplementary Fig. 7a and Table S3 ). Three main groups of secreted factors were identified in the 54-factor secretome. In the first group, secreted factors such as matrix metallopeptidase 9, matrix metallopeptidase 2, bone morphogenetic protein 1, lysyl oxidase-like 2 (MMP9, MMP2, BMP1, LOXL2 respectively) and elastin Percentage of BrdU incorporation microfibril interfacer 2 (EMILIN2) were increased in Pten −/− MMFs. Re-introduction of miR-320 into the cells resulted in decreased expression of these secreted factors to near-normal levels (Fig. 4a, group I) , suggesting that they may represent direct targets of miR-320. In the second group, secreted factors such as thrombospondin 1 (THBS1) and secreted frizzled-related protein 1 (SFRP1) were downregulated in Pten −/− MMFs and re-introduction of miR-320 restored their expression (Fig. 4a, group II) , and thus probably represent indirect targets of miR-320. Importantly, overexpression of anti-miR-320 ( Supplementary Fig. S2e ) led to an increase in the secretion of MMP9, MMP2, LOXL2 and EMILIN2 and a decrease in the secretion of THBS1 and SFRP1 (Fig. 4a, groups I and II) . The third group of factors, represented by cathepsin B (CTSB), was markedly increased in Pten −/− MMFs but remained unaffected by miR-320 re-expression (Fig. 4a , group III). Conditioned media had no effect on the expression of the miR-320 targets in DB7 cells (Supplementary Fig. S4c ).
Two members of the Pten-regulated secretome were selected for further analysis, MMP9 and EMILIN2, which are thought to be involved in the control of epithelial-cell migration 26 and angiogenesis 27 . Blocking MMP9 expression from stromal fibroblasts either by Mmp9-specific short interfering RNA (siRNA) or by treating conditioned media with an MMP9-specific antibody blunted the ability of conditioned media derived from Pten-null MMFs to promote the migration of DB7 cells (Fig. 4b,c) . Similarly, blocking EMILIN2 expression by either Emilin2-specific siRNA or antibody reduced the ability of Pten-null MMF conditioned media to stimulate endothelial cell proliferation (Fig. 4d,e) . Thus, these results indicate that miR-320 regulates a fibroblast secretome required for remodelling of the extracellular matrix and vascular network.
Ets2 is a direct target of miR-320
Of the stromal-secreted proteins identified, only seven were predicted by miR/target-recognition software to represent direct targets of miR-320 (Supplementary Table S3 ), indicating that regulation of this secretome may predominantly be an indirect consequence of miR-320 downregulation. Interestingly, Ets2 was among the genes predicted to be directly regulated by miR-320 ( Supplementary Fig. S5a ). Moreover, promoter/enhancer sequences in 20 genes of the 54-factor secretome (37%) contain ETS2-binding elements that are conserved across species [28] [29] [30] [31] [32] [33] (Supplementary Table S4) , including Mmp9, which is a known bona fide transcriptional target of ETS2 (ref. 6 ). Based on the observed correlative relationship between PTEN, ETS2 and miR-320 expression in both MMFs and breast cancer samples, and the above in silico predictions, we entertained the possibility that ETS2 may be −/− MMFs expressing siRNA negative control (NC) (n = 3) or siRNA against Emilin2 (n = 3). EMILIN2 downregulation was verified by Western blot using EMILIN2 antibody. Scale bars, 100 µm. Quantification of BrdU incorporation expressed as mean ± s.d., * P < 0.01. (e) Representative images of BrdU incorporation in endothelial cells in the presence of conditioned medium from Pten −/− MMFs precleared with IgG (n = 3) or IgG precoupled with α-EMILIN2 (n = 4). Western blots using EMILIN2 antibody in precleared and input control samples were carried out as a control. Scale bars, 100 µm. Quantification of BrdU incorporation expressed as mean ± s.d., * P < 0.01. Full-length blots are presented in Supplementary Fig. S7a. acting downstream of miR-320 to regulate the expression of a large fraction of the 54-factor secretome.
Consistent with this hypothesis, reintroduction of miR-320 in Pten-null MMFs led to a decrease in ETS2 protein levels, and, conversely, overexpression of the anti-miR-320 in wild-type fibroblasts increased ETS2 protein to levels found in Pten −/− MMFs ( Fig. 5a and Supplementary Fig. S7b) ; no significant effects on the signalling pathways of AKT, mitogen-activated protein kinase 8/9 (JNK1/2; also known as MAPK8/9) and Eph receptor B2 (ERK; also known as EPHB2), known to be upstream activators of ETS2 (ref. 6), were observed on manipulation of miR-320 levels ( Supplementary  Fig. S5b ). To test if miR-320 directly regulates ETS2, we examined the ectopic expression of an Ets2 full-length complementary DNA with an authentic 3 untranslated region (3 UTR) containing the predicted miR-320 target sequences. Co-transfection of miR-320 along with this full-length Ets2 cDNA vector resulted in a marked decrease in ectopic ETS2 protein levels. Mutation of the predicted miR-320 target sequences in the Ets2 3 UTR abolished this effect (Fig. 5b and Supplementary Figs S5c, S7b) . Moreover, introduction of the Ets2 3 UTR into a luciferase reporter gene was sufficient to modulate reporter expression in response to miR-320 ( Supplementary Fig. S5d) .
In silico analysis also predicted Mmp9 and Emilin2 to be direct targets of miR-320. Employing an experimental strategy similar to that described above, we could show that Mmp9 and Emilin2 are directly regulated by miR-320 through their 3 UTR target sequences ( Fig. 5c and Supplementary Figs S5c, S7c; luciferase reporter gene assays in Supplementary Fig. S5d ). Exogenous introduction of miR-320 into Pten-null MMFs also led to decreased Ets2, Mmp9 and Emilin2 mRNA levels ( Supplementary Fig. S5e ). These results are consistent with a dual mechanism for the regulation of Mmp9 expression that involves transcriptional control by ETS2 (ref. 6 ) and posttranscriptional control by miR-320. −/− MMFs were transiently transfected either with siRNA negative control (NC) or siRNA against Akt1, Mapk8 /Jnk1, Mapk9 /Jnk2 or the combination of Mapk8 /Jnk1 and Mapk9 /Jnk2. AKT and JNK phosphorylation status was verified by Western blot using anti-phospho-specific antibodies, and compared with total kinase levels using non-discriminating antibodies. Tubulin was used as a loading control. Expression of miR-320 was validated by qrtPCR (n = 3). Mean relative miR expression level ±s.d. is shown. Full-length blots are presented in Supplementary Fig. S7b-d. Loss of Pten leads to activation of the phosphatidylinositol 3 (PI3)-kinase/AKT pathway, which is believed to be the pathway responsible for the majority of phenotypes associated with loss of PTEN in human tumours 34 . However, Pten loss has also been shown to activate further signalling pathways, including AKT-independent activation of the JNK pathway 35, 36 . Based on preliminary results using small-molecule inhibitors for PTEN-regulated pathways (data not shown), we focused on AKT1, JNK1/MAPK8 and JNK2/MAPK9 using the more specific approach of siRNA-mediated knockdown ( Fig. 5d and Supplementary  Fig. S7d ). These experiments demonstrated that knockdown of either Jnk1/Mapk8 or Jnk2/Mapk9 in Pten-null fibroblasts led to a two-to threefold increase in miR-320 expression, and knockdown of both led to a fivefold increase in miR-320 expression. In contrast, knockdown of Akt1 had no significant effect on miR-320 expression.
Pten: +/+ +/+ +/+ -/--/--/-
A mouse stromal miR-320 profile predicts human breast cancer patient outcome To explore the clinical relevance of our findings, we used the mouse-derived 54-secretome profile identified above to query stroma-specific expression profiles of breast cancer patients 37 . Human homologues of the mouse 54-factor secretome profile were differentially expressed in tumour versus adjacent normal stroma 38 , leading to a partial segregation of tumour stroma and normal stroma that attained statistical significance (Fig. 6a and Supplementary  Table S5 ). Importantly, the 54-factor secretome profile correlated with clinical outcome based on stromal gene expression in breast cancer patients 37 (Fig. 6b) . Given the role of Ets2 in regulating the expression of a subset of these 54 genes (20/54), we also used this miR-320/Ets2-regulated 20-gene subset to query the same stroma-specific expression profiles derived from breast cancer patients. As shown in Fig. 6c , the 20-gene Ets2 subset differentiated tumour stroma from adjacent normal stroma even more effectively than the complete 54-gene list (Fig. 6c and Supplementary Table S5 ) and robustly correlated with patient outcome (Fig. 6d) . The 54-or the 20-gene secretome profiles, when used to query further expression profiles derived from whole tumours and linked to breast cancer patient outcome data 39 , also correlated with patient outcomes (Supplementary Fig. S6a,b) .
DISCUSSION
Here, we have identified a Pten-miR-320-Ets2 tumour-suppressor axis in stromal fibroblasts that modulates the intercellular communication within the tumour microenvironment and is responsible for pathological and molecular events observed in malignant human breast cancer. Loss of Pten in stromal fibroblasts results in downregulation of miR-320 and the reprogramming of mRNA expression profiles in neighbouring endothelial and epithelial cells of the mammary gland. We show that, by influencing the behaviour of multiple cell types, miR-320 in stromal fibroblasts is a critical Pten-regulated determinant for the suppression of epithelial tumours. Despite identifying a critical function for the miR-320-Ets2 pathway in the stroma, our results do not show that the miR-320-Ets2 pathway is strictly stromal specific. The pathway could also be active in epithelial tumour cells that have low PTEN expression, although the PTEN immunohistochemistry (IHC) results indicate that in the majority of human breast cancer patients the pathway is unlikely to be active in both cell compartments.
Proteomic analysis of fibroblast-conditioned medium identified a miR-320-regulated tumour-promoting secretome that when activated by loss of Pten incites profound changes in endothelial and epithelial cell phenotypes typical of malignant tumours. While some of the mRNAs encoding these secreted factors are targeted by miR-320 directly, for example Emilin2, most are regulated indirectly through transcriptional control by ETS2, which is itself an essential direct target of miR-320. Together, these findings expose a miR-320 regulatory switch in normal fibroblasts that operates in a cell-autonomous fashion to inhibit the expression of a tumour-promoting secretome and in a cell-non-autonomous fashion to block expression programmes in other cell types in the microenvironment that together suppress tumour-cell growth and invasiveness. Remarkably, bioinformatic analyses demonstrated that a miR-320 secretome signature could distinguish normal from tumour stroma and could be used to robustly predict outcome in breast cancer patients, underlining the potential clinical impact of the stromal Pten-miR-320 regulatory axis on human breast cancer.
In conclusion, our results extend the concept of miR function beyond the tumour cell boundary by defining a complex network NPC2  CTSZ  CTSB  CPE   LOXL2  THBS1  LOX  OGN  CPE  SFRP1  MMP19  EMILIN2  RARRES2  LRP1  EMILIN1  ECM1  EFEMP2 LGALS3BP The permutation P value of the log-rank test statistic between risk groups is based on 1,000 permutations.
of communication within the tumour microenvironment that is necessary for tumour growth and spread. In spite of the overwhelming complexity, modulation of a few key regulatory nodes such as miR-320 may be sufficient to impede the most malignant properties of tumour cells, suggesting strategies for developing agents that disrupt select tumour microenvironment networks. 
METHODS
Methods
DOI: 10.1038/ncb2396 METHODS
Cell culture. Primary Pten +/+ or Pten −/− MMFs were purified as previously described 6 . Pten −/− MMFs were immortalized using a 3T3 protocol 40 . MMFs, DB7 ( 16) and COS7 cells were cultured in DMEM containing 10% fetal bovine serum under standard conditions. Endothelial cells were cultured in DMEM-F12 containing 20% fetal bovine serum plus 30 µg ml −1 endothelial-cell growth supplement (Upstate Biotechnology) and 10 U ml −1 heparin (Sigma-Aldrich). miR profiling and quantitative PCR. Total RNA was extracted using Trizol (Invitrogen) and treated with RNase-free DNase (Qiagen). MicroRNA profiling was carried out as described previously 41 . Mature miR expression analysis by qrtPCR was carried out using the miR real-time PCR detection kit (Applied Biosystems) as described previously 42 . Quantitative real-time PCR expression analysis with reverse transcription was carried out using Power SYBR Green (Applied Biosystems) with mouse Ets2, Mmp9 and 18S ribosomal RNA primers. Primer sequences (5 -3 ) were: Mmp9, 5 -cattcgcgtggataaggagt-3 and 5 -tcacacgccagaagaatttg-3 ; Ets2, 5 -ccaaaaggagcaacgacgtct-3 and 5 -ttcatgccaaactggtgcag-3 ; 18S rRNA, 5 -aactttcgatggtagtcgccg-3 and 5 -ccttggatgtggtagccgttt-3 .
Microarray analysis. Fibroblasts and epithelial cells were isolated from mammary glands of wild-type mice or mice with Pten-null fibroblasts by methods described previously 6 . Endothelial cells in collagenase-dispersed tissue from these same mammary glands were labelled with CD31 fluorescently tagged antibody (BD Pharminogen) and enriched using fluorescence-activated cell sorting. RNA was collected with Trizol (Invitrogen). RNA samples were hybridized to Affymetrix Mouse Exon 1.0 ST Array platform. Data were processed using Affymetrix Expression Console software. The Robust Multichip Average method was used to do background correction, quantile normalization, and expression level summarization. For each cell compartment, twofold differentially expressed genes at a significance level of P < 0.05 were determined by using BRB-Array Tools 3.8.1. For construction of heat maps, the geometric means of genes from wild-type samples in each cell compartment are set as references, and the colours (from blue to red) represent the ratio between the gene expression in samples and the references. Global gene-expression data from the three cell compartments was also analysed by principal component analysis using the Statistical R package. The first three principal components explained the largest variation of gene-expression differences.
The microarray data were deposited with Gene Expression Omnibus and can be viewed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token= dncnfwwoqoqyexc&acc=GSE24501.
Vector construction and transfection. The lentiviral pMIR-GFP, pMIR-GFPcontaining miR-320 precursor RNA, pCMV-SPORT6 Ets2 full-length and pCMV-SPORT6 Mmp9 full-length vectors were purchased from Open BioSystem, and pCMV6 Emilin2 full-length vector was purchased from OriGene.
The 3 UTRs encompassing the target sequence for miR-320 of Ets2 and Mmp9 cDNAs were cloned into the pMIR-REPORT vector (Ambion). Luciferase reporter vector pEZX-MT01 containing the full-length 3 UTR of the Emilin2 gene was purchased from GeneCopoeia. Luciferase reporter assays were carried out as previously described 43 . For the mutated construct of pCMV-SPORT6 Ets2 the QuickChange Site-Directed Mutagenesis Kit (Stratagene) was used to alter the miR-320 seed sequence. Transfection (25-75 nmol l −1 ) of scrambled miR, pre-miR-320 and anti-miR-320 (Ambion) or pMIR-REPORT was done with Lipofectamine 2000 (Invitrogen).
The pMIR-lentiviral constructs along with lentiviral packaging constructs (System Biosciences) were used to establish Pten −/− MMF lines constitutively overexpressing GFP or GFP-miR-320 ( Supplementary Fig. S3c) .
siRNA for Mmp9 (5 -CTGGAAGGTATTATGTAACTA-3 ), Emilin2 (5 -AGGCGTTGTTCTCTTCAATAA-3 ), Akt1 (5 -CATGCTGTTCAGAGACATTTA-3 ), Mapk8 (5 -ATGAAGTGTGTTAATCACAAA-3 ) and Mapk9 (5 -ACCGTCAT-ATATCATATCTTA-3 ) were purchased from QIAGEN.
Xenograft assays. All use of animals was in accordance with all US National Institutes of Health regulations and were approved by the Ohio State University Institutional Animal Care and Use Committee. Female NcR nude mice were purchased from Taconic. For cell co-injections, 1.5 × 10 6 DB7 cells (stably transfected with pDSRed2-C) and 0.5 × 10 6 MMFs (infected or transfected, as shown in figure legends) were suspended in a 0.2 ml mixture of serum-free DMEM and ice-cold Matrigel (BD Biosciences) at a 1:1 ratio and injected subcutaneously. Each nude mouse was injected at two sites, one each for control and experimental admixtures (see figure legends). For tumour formation assays mice were killed 4 weeks after injection; for angiogenesis and BrdU incorporation analyses mice were killed 5 days after cell injections. Tumours (4 weeks) or Matrigel composites (5 days) were collected, weighed and either fixed immediately in 10% formalin and embedded in paraffin, or frozen in OCT. Histological sections 30 µm in thickness were prepared for evaluation of RFP and GFP expression, or CD31 (1:40 antibody dilution) and BrdU immunostaining. Confocal microscopy was carried out as previously described 44 .
ISH and IHC of human TMAs. TMAs were constructed from de-identified invasive breast carcinoma patient samples (n = 126). The TMAs consisted of three cores for each tumour sample shown along with three cores of adjacent normal tissue from the same patient. If the adjacent normal samples lacked staining for either miR-320 ISH or PTEN IHC, the samples were excluded from the final analysis (see below). The protocol for detection of miRs by ISH has been previously published 17 . The sequences of the probes (Exiqon) containing the locked nucleic acid/digoxigeninmodified bases were as follows: hsa-miR-320, tcgccctctcaacccagctttt; miR-SC, cgtataggcccaagaattagg. IHC staining for PTEN (1:200) and pT72-ETS2 (anti-peptide rabbit polyclonal 1:40) was carried out as previously described 6 . The Nuance System was used for visualization of ISH and IHC staining as previously described 43 .
Preparation of conditioned media and three-dimensional assays. MMFs were cultured until 90% confluent; cells were rinsed twice with serum-free medium, and subsequently incubated in serum-free DMEM for 36 h. The conditioned media were collected and used for in vitro assays or for proteomic analysis. A previously described spheroid migration assay was adapted to mammary tumour cells 44 . Briefly, 8,000 DB7 cells in a 20 µl drop of medium formed mammospheres after 4 days of incubation. The mammospheres were sandwiched between two layers of collagen I in the presence of conditioned medium and quantified as previously described 44 . The vessel-forming ability of endothelial cells was characterized in vitro using a Matrigel sandwich assay as previously described 45, 46 . ImageJ software (http://rsb.info. nih.gov/ij) was used for quantification of endothelial-cell recruitment into branched networks in vivo and in vitro using the Analyse Skeleton plugin and Analyse Particles function of binary images with automatic threshold.
BrdU incorporation assay. Cell proliferation was measured using a commercial
BrdU assay kit (Roche) following the manufacturer's instructions. BrdU incorporation assays for in vivo studies were carried out as previously described 47 . Image J software using the Cell Counter plugin was used to quantify the results.
Proteomic analysis. All mass spectra were acquired at the Proteomics Shared
Resource at The Ohio State University. Samples were subjected to nano-liquid chromatography/tandem mass spectrometry to provide internal sequences of the proteins present. Sequence information from the tandem mass spectrometry data was processed using MASCOT 2.0 (Matrix Science). Cell-protein extraction and Western blot analysis was done as described previously 48 . Antibodies used were as follows: LOXL2, MMP2, EMILIN2 (1:500, Santa Cruz Biotechnology), THBS1, THBS2, SFRP1 (1:1,000, R&D Systems), ETS2 (1:1,000, rabbit polyclonal affinity purified), MMP9 (1:1,000, Abcam), BMP1 (1:500, Oncogene), β-actin, α-tubulin (1:10,000, Sigma Aldrich), CTSB, PTEN, AKT, P-AKT S473 , JNK, P-JNK T183/Y185 , ERK and P-ERK T202/Y204 (1:1,000, Cell Signaling).
Statistical analysis.
For tumour studies (Fig. 1c) , an analysis-of-variance model with adjusted pairwise comparisons was used: Pten +/+ versus Pten −/− (n = 7) and Pten −/− versus Pten −/− /miR-320 (n = 9). Holm's method was used to control false positives 49 . For human TMA studies (Fig. 2a) , a nonparametric sign test was used to test paired scores between normal and cancer samples. For dual staining of human TMAs, the Spearman correlation method was used to evaluate the association of scores ( Fig. 2a and Supplementary Fig. S2a) .
A two-sample Student t -test was used for migration, proliferation and angiogenic assays (Figs 1d,e, 3a-d, 4b-e and Supplementary Figs S1d-e).
Generating human stroma heat maps with genes identified from analysis of the miR-320/Pten-null MMFs. Genes corresponding to the 54-factor whole secretome identified and the subset of 20 ETS2 targets were queried against the McGill Cancer Center's microarray data on normal and tumour stroma of breast cancer patients (GSE4823; ref. 38). 40 of the 54 genes, and 13 of the 20 ETS2-target genes, were represented on the Custom Agilent Array used in the McGill study 37 . For each of these two gene lists, a heat map was generated on the human stroma dataset (52 normal stroma and 49 tumour stroma samples). The heat maps show the ability of the two gene sets to separate the normal and tumour stroma samples based solely on their gene-expression profiles. The permutation test strategy (10,000 random permutations) was used to confirm that the gene signatures specifically discriminate between human tumour and normal stroma samples.
Kaplan-Meier curves for survival risk prediction using principal component analysis with genes identified from analysis of the miR-320/Pten-null mouse fibroblasts. All analyses were carried out using BRB-Array Tools.
The Survival Risk Group Prediction Tool was used to analyse whether the NATURE CELL BIOLOGY miR-320/Pten-related 54-gene signature (40 human orthologues) and the 20 ETS2-target genes (13 human orthologues) have a statistically significant association with the survival data for patients within each dataset. This regression model enables the analysis of survival risk for each individual as a function of the logged gene-expression values. The subset of genes that correlated with time through a univariate analysis was obtained using a Cox threshold significance level of 0.05. The evaluation of the predictive method was cross-validated using the tenfold cross-validation. The statistical significance for the survival curves was found by calculating the log-rank statistical P value by carrying out 1000 permutations. All other parameters were set to the default values. The McGill stromal database (GSE4823, Fig. 6b,d ) and the Stockholm whole-tumour database (GSE1456 Supplementary Fig. S5a,b) were used for the analyses. Table S2 Spearman correlations between PTEN, P-ETS2 T72 and miR-320 expression in stroma and/or epithelium based on Allred scores of the tissue microarray (See Methods).
Table S3
List of secreted proteins identified by mass spectrometry in conditioned medium from Pten -/-MMFs transfected with either miR negative control (NC) or miR-320 precursor. Mir-320 targets, predicted in silico (www.microran.org; www.targetscan.org) are indicated in red.
Table S4
List of secreted proteins identified by mass spectrometry in conditioned medium from Pten -/-MMFs with conserved ETS2 binding sites in 5' noncoding region. Figure 6A and list of 13 Ets2-target genes shown on the heatmap on Figure 6c (in order of appearance).
